The clinical spectrum of Fontan-associated liver disease: results from a prospective multimodality screening cohort.
Adult
Biomarkers
/ blood
Biopsy
/ standards
Elasticity Imaging Techniques
/ methods
Female
Fontan Procedure
/ adverse effects
Humans
Hypertension, Portal
/ diagnosis
Liver
/ diagnostic imaging
Liver Cirrhosis
/ blood
Magnetic Resonance Imaging
/ methods
Male
Multimodal Imaging
/ methods
Prognosis
Prospective Studies
Severity of Illness Index
Tomography, X-Ray Computed
/ methods
Ultrasonography
/ methods
Varicose Veins
/ epidemiology
Fontan
Fontan-associated liver disease
Liver biopsy
Liver fibrosis/cirrhosis
Nodules
Screening
Journal
European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263
Informations de publication
Date de publication:
01 04 2019
01 04 2019
Historique:
received:
16
04
2018
revised:
04
07
2018
accepted:
14
09
2018
pubmed:
23
10
2018
medline:
6
6
2020
entrez:
23
10
2018
Statut:
ppublish
Résumé
Liver fibrosis and cirrhosis are a consequence of a Fontan physiology, and determine prognosis. It is unclear whether non-invasive assessment of liver pathology is helpful to provide clinically relevant information. The aims of this study were to assess the spectrum of Fontan-associated liver disease (FALD) and usefulness of non-invasive methods to assess biopsy confirmed liver fibrosis. Hepatic screening of consecutive patients consisted of a blood panel, ultrasonography, elastography, contrast-enhanced magnetic resonance imaging (MRI)/computed tomography (CT) scan, and liver biopsy (scored with Fontan specific fibrosis scores and collagen proportionate area; CPA). Fibrosis parameters, varices, ascites, and splenomegaly were measured on imaging. Thirty-eight of 49 referred patients (27 ± 6.6 years, 73.7% male) underwent the complete screening protocol. Liver fibrosis on biopsy was present in all patients, and classified as severe (Stages 3-4) in 68%. Median CPA was 22.5% (16.9-29.5) and correlated with individual fibrosis scores. ELF® and liver stiffness were elevated, but MELD-XI scores were low in all patients. Fibrosis severity neither correlated to ELF® and liver stiffness, nor to (semi-) quantitative fibrosis parameters on MRI/CT. Varices were present in 50% and hyperenhancing nodules in 25% of patients, both independent of fibrosis stage, but varices were associated with higher CPA values. The FALD spectrum includes both hepatic congestion and severe fibrosis, with signs of portal hypertension and hyperenhancing nodules as significant manifestations. Routine imaging, transient elastography, and serum biomarkers are unable to accurately assess severity of liver fibrosis in this cohort. Future research should focus on validating new diagnostic tools with biopsy as the reference standard.
Identifiants
pubmed: 30346512
pii: 5128919
doi: 10.1093/eurheartj/ehy620
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1057-1068Informations de copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.